Effect of Intravenous Heparin Administration on Duration of Hospitalization

Dunn, Andrew; Bioh, Dominic; Beran, Mindy; Capasso, Marco; Siu, Al
February 2004
Mayo Clinic Proceedings;Feb2004, Vol. 79 Issue 2, p159
Academic Journal
• Objective: To determine how frequently hospital discharge is delayed to administer intravenous heparin to patients with diverse indications for oral anticoagulation (OAC) medications and how often these delays are potentially avoidable, as assessed by the prevalence of contraindications to outpatient use of low-molecular-weight heparin (LMWH). • Patients and Methods: Records were reviewed from a random sample of 309 patients who received at least 1 dose of OAC medication while hospitalized at the Mount Sinai Hospital in New York City between January I and December 31, 1997. Medical records were abstracted to determine admission diagnoses; patient demographics and comorbid conditions; indications for anticoagulation; laboratory data; and treatment and discharge medications, including whether LMWH was prescribed. A delay was defined as the continuation of hospitalization solely to administer intravenous heparin. Predefined criteria were used to classify the delay of discharge as appropriate or avoidable on the basis of the patient's potential eligibility for outpatient treatment with LMWH. • Results: Discharge was delayed for 75 of 309 patients (24%; 95% confidence interval [CI], 19%-29%); during analysis of the avoidability of delay, 67 of the 75 medical records were available and showed that 32 of 67 delays (48%; 95% CI, 35%-60%) were avoidable. Of patients taking long-term OAC medications who were admitted for reasons unrelated to thromboembolism or bleeding, discharge was delayed for 18 of 146 (12%; 95% CI, 7%19%); during analysis of the avoidability of delay, 16 of the 18 medical records were available and showed that 9 of 16 delays (56%; 95% CI, 30%-80%) were avoidable. Of patients admitted for acute venous thromboembolism who were not taking long-term OAC medications, discharge was delayed for 24 of 38 (63%; 95% CI, 46%-78%); during analysis of the avoidability of delay, 22 of the 24 medical records were available and showed that 11 of 22 delays (50%; 95% CI, 28%-72%) were avoidable. • Conclusions: For patients taking OAC medications, hospital discharge is frequently delayed so that intravenous heparin can be administered; approximately half of these delays could be avoided by outpatient use of LMWH. Studies of the safety, efficacy, and feasibility of outpatient use of LMWH for indications other than deep venous thrombosis are needed because timely discharge of these patients could substantially decrease health care costs.


Related Articles

  • The Treatment of Proximal Vein Thrombosis with Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin. Hull, Russell D.; Raskob, Gary E.; Pineo, Graham F.; Brant, Rollin F. // Clinical & Applied Thrombosis/Hemostasis;Spring1995, Vol. 1 Issue 2, p151 

    Low-molecular-weight heparin, compared with unfractionated heparin, has a higher bioavailability and a more prolonged half-life. There are limited data comparing the use of low-molecular-weight heparin with unfractionated heparin for the treatment of deep vein thrombosis. We have compared...

  • Use of Enoxaparin for Anticoagulation Therapy. Sadovsky, Richard // American Family Physician;2/1/2000, Vol. 61 Issue 3, p842 

    Discusses research on the use of enoxaparin in anticoagulation therapy. Reference to a study by J. M. Spandorfer, et al., from the August 15, 1999 issue of the `American Journal of Cardiology'; Effectiveness of heparin in anticoagulation therapy; Assessment on patients who are receiving...

  • The Weight-based Heparin Dosing Nomogram Compared with a "Standard Care" Nomogram. Raschke, Robert A.; Reilly, Brendan M.; Guidry, James R.; Fontana, Joseph R.; Srinivas, Sandhya // Annals of Internal Medicine;11/1/93, Vol. 119 Issue 9, p874 

    Focuses on a study which determined whether an intravenous heparin dosing nomogram based on body weight achieves therapeutic anticoagulation more rapidly than a standard care program. Methods; Results; Discussion.

  • Enoxaparin sodium/heparin/nadroparin calcium.  // Reactions Weekly;1/31/2009, Issue 1237, p9 

    The article describes the cases of four patients who developed allergic contact dermatitis to enoxaparin sodium, heparin or nadroparin calcium. The patients subsequently demonstrated cross-reactivity to other heparins on skin testing. Patient 1 received heparin calcium during an episode of...

  • LMWHs cost-effectively treat DVT with low side effects. McCue // Managed Healthcare;Dec99, Vol. 9 Issue 12, p38 

    Relates the need for health maintenance organizations in the United States to include low-molecular weight heparins (LMWH) in their anticoagulation services. Effectiveness of LMWH in treating deep-vein thrombosis (DVT); Reduction in the costs of treating DVT due to the advent of LMWH; Side...

  • Treatment of the Patient with Deep Vein Thrombosis. Weismantel, David // Journal of Family Practice;Mar2001, Vol. 50 Issue 3, p249 

    The article discusses an evidence-based approach to treating deep vein thrombosis (DVT) in diagnosed patients. To be able to prevent further embolization and recurrence of venous thromboembolic disease, it is recommended that patients with DVT be given heparin for anticoagulation. Heparin...

  • Control and Management of Heparin Therapy in Venous Thromboembolism. Almazán, A.; Lozano, F.; Ramos, M.; Gómez-Alonso, A. // Vascular Surgery;Jan/Feb1983, Vol. 17 Issue 1, p1 

    The precise management of Deep Venous Thrombosis (DVT), and its complications, is of considerable clinical importance as well as being a controversial topic. However, the standard treatment or complementary of others, as well as the one accepted as being of less risk and more effectiveness is...

  • Subcutaneous Heparin Compared with Continuous Intravenous Heparin Administration in the Initial Treatment of Deep Vein Thrombosis. Hommes, Daan W.; Bura, Alessandra; Mazzolai, Lucia; Buller, Harry R.; ten Cate, Jan W. // Annals of Internal Medicine;2/15/92, Vol. 116 Issue 4, p279 

    Deals with a study which assessed the efficacy and safety of published randomized trials comparing subcutaneous heparin with continuous intravenous heparin for the initial treatment of deep vein thrombosis. Evidence for the use of heparin as antithrombotic drug; Identification of clinical...

  • Cost comparison of enoxaparin vs. unfractionated heparin. APGAR, BARBARA // American Family Physician;10/15/1998, Vol. 58 Issue 6, p1435 

    Presents the abstract of the article `Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial,' by D.B. Mark, et al. from the `Circulation' journal dated May 5, 1998.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics